| 现在位置：首页赵丽淑个人主页 [English] | ||||
 |
||||
| 苏州大学，苏州工业园区仁爱路199号，215123，苏州 电邮：zhaolishuemily[AT]126.com |
||||
| 个人简历 | ||||
| 1995年4月 | 出生于湖南邵阳 | |||
| 2010 - 2013 | 邵东市第三中学（高中） | |||
| 2013 - 2018 | 中南大学湘雅医学院（本科） | |||
| 2018 - 2021 | 中南大学湘雅二医院（硕士） | |||
| 2021 - 至今 | 苏州大学放射医学与防护学院、同济大学附属上海市肺科医院肿瘤科（联培博士研究生） | |||
| 研究方向 | ||||
| 主要从事肺癌靶向及免疫治疗相关研究，核医学探针的制备及应用研究 | ||||
| 代表性论文 | ||||
| 1.Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications Lishu Zhao, Hao Wang, Kandi Xu, Xinyue Liu, Yayi He* Chin Med J (Engl), 2022, 135(10), 1203-1212. 2. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers Chunhong Hu#, Lishu Zhao#, Wenliang Liu#, Songqing Fan, Junqi Liu, Yuxuan Liu, Xiaohan Liu, Long Shu, Xianling Liu, Ping Liu, Chao Deng, Zhenhua Qiu, Chen Chen, Yi Jiang, Qingchun Liang, Lingling Yang, Yang Shao, Qiongzhi He, Danlei Yu, Yue Zeng, Yizheng Li, Yue Pan, Sujuan Zhang, Shenghao Shi, Yurong Peng, Fang Wu* J Immunother Cancer, 2021, 9(12), e003773. 3. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer Peixin Chen#, Lishu Zhao#, Hao Wang, Liping Zhang, Wei Zhang, Jun Zhu, Jia Yu, Sha Zhao, Wei Li, Chenglong Sun, Chunyan Wu, Yayi He*, Caicun Zhou J Immunother Cancer, 2021, 9(8), e002554. 4. Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer Hui Sun#, Jiawei Dai#, Lishu Zhao#, Jun Zhu, Hao Wang, Peixin Chen, Hui Lu*, Qiankun Chen*, Zhemin Zhang* Ann Transl Med, 2021, 9(18), 1468. 5. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC Yayi He#, Linsong Chen#, Lishu Zhao, Shiying Dang, Guifeng Liu, Shinji Sasada, Patrick C Ma, Nico van Zandwijk, Rafael Rosell, Helmut H Popper, Hao Wang, Minlin Jiang, Haoyue Guo, Xinyi Liu, Shifu Chen, Xiaoni Zhang, Mingyan Xu, Bo Zhu*, Ming Liu*, Caicun Zhou* Theranostics, 2021, 11(14), 7092-7109. 6. Microbes in lung cancer initiation, treatment, and outcome: Boon or bane? Haoyue Guo, Lishu Zhao, Junjie Zhu, Peixin Chen, Hao Wang, Minlin Jiang, Xiaogang Liu, Hui Sun, Wencheng Zhao, Zixuan Zheng, Wei Li, Bin Chen, Qiyu Fang, Menghang Yang, Yayi He*, Yang Yang* Semin Cancer Biol, 2021, ;S1044-579X(21)00154-1. 7. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment Peixin Chen, Hao Wang, Lishu Zhao, Haoyue Guo, Liping Zhang, Wei Zhang, Chenglong Sun, Sha Zhao, Wei Li, Jun Zhu, Jia Yu, Chunyan Wu, Yayi He* Front Oncol, 2021, 11, 713853. 8. Multiple primary lung cancers: a new challenge in the era of precision medicine Lishu Zhao, Chaoyuan Liu, Guiyuan Xie, Fang Wu*, Chunhong Hu*.? Cancer Manag Res, 2020, 12, 10361-10375. 9. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study Yanjun Zhong#, Lishu Zhao#, Guobao Wu, Chunhong Hu, Chenfang Wu, Min Xu, Haiyun Dong, Quan Zhang, Guyi Wang, Bo Yu, Jianlei Lv, Chao Wu, Siye Zhang, Chenghui Cao, Long Shu, Yue Pan, Xianling Liu, Fang Wu* J Int Med Res, 2020, 48(12), 300060520979151. 10. The multidisciplinary team plays an important role in the prediction of small solitary pulmonary nodules: a propensity-score-matching study Chaoyuan Liu, Lishu Zhao, Fang Wu, Yeqian Feng, Rong Jiang, Chunhong Hu* Ann Transl Med, 2019, 7(23), 740. |
||||
| 返回顶部 | ||||